SIRT With Tremelimumab and Durvalumab for Resectable HCC
Clinical trial NCT05701488 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05701488
- Sponsor
- Jiping Wang, MD, PhD
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-21
- Primary completion
- 2026-10-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.